CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
R-Pharm›
Library
R-Pharm

R-Pharm

R-Pharm is a Russian pharmaceutical manufacturer serving patients and healthcare systems through full-cycle drug development and production.

Operating headquarters
Moscow, RU🇷🇺
Founded
2001
Loading
Overview
Compare
Employees
News
Library

R-Pharm - Library

r-pharm.com·

Topics

Publication type

Content origin
Row density

Coverage

8 items
  1. R-Pharm Sues Raiffeisenbank for €337.5 Million in Legal Disputeglobalbankingandfinance.com/RUSSIA-COURT-RAIFFEISEN-BANK-INTERNATIONAL-c767b049-4730-47d4-a74e-0c70bd716fd3/

    Moscow-based biotech firm R-Pharm International sues Raiffeisen’s Russian unit for €337.5 million, court filings show. The claim is also reported as $390 million.

    Aug 2025 · Global Banking & Finance ReviewNews article

  2. R-Pharm has launched a platform for the creation of innovative therapeutic antibodies | Newsgxpnews.net/en/2025/05/r-pharm-has-launched-a-platform-for-the-creation-of-innovative-therapeutic-antibodies/

    R-Pharm Group has launched a platform to create innovative therapeutic antibodies at the Laboratory for the Early Development of Biological.

    May 2025 · GxP NewsNews article

  3. New pharmaceutical plant to be built in St. Petersburg special economic zonerunews24.ru/eng/saint-petersburg/06/08/2024/new-pharmaceutical-plant-to-be-built-in-st-petersburg-special-economic-zone

    R-Pharm is to build a pharmaceutical plant in St. Petersburg’s special economic zone. The enterprise is to supply medicines for the city’s beneficiaries. Before construction works begin, R-Pharm bought a part of Baltfarma LLC.

    Aug 2024 · RuNews24.ruNews article

  4. Russian drugmaker R-Pharm eyes buying Takeda plant in Yaroslavlthepharmaletter.com/generics-news/russian-drugmaker-r-pharm-eyes-buying-takeda-plant-in-yaroslavl

    R-Pharm is eyeing the purchase of Takeda’s plant in Yaroslavl. The supplied text gives no further details about the facility or a potential transaction.

    Aug 2023 · thepharmaletter.comNews article